Skip to main content
x
Ask About Clinical Trials on Day One

Ask About Clinical Trials on Day One

(Mitch Jelniker) - For people diagnosed with small cell lung cancer, the clinical trial conversation belongs in the very first appointment.

A diagnosis of SCLC can trigger a whirlwind of appointments, tests, and decisions. But amid all that noise, there is one question patients should ask their doctor as early as possible:

“Is there a clinical trial that might be right for me?”

Many patients may associate that question with running out of treatment options. But according to Dr. Ashish Saxena, Chief of Thoracic Medical Oncology at Weill Cornell Medicine, that’s not always the case.

Some clinical trials are available only before treatment begins, while others are studying promising therapies as a first treatment. For someone facing a fast-moving cancer like SCLC, timing is everything.

“There are a lot of changes going on in the landscape today, more than we've seen for a very long time. Emerging treatments now involve immunotherapy, where your immune system attacks small cell lung cancer. Studies are also exploring antibody-drug conjugates, antibodies that target specific proteins in small cell cancer and deliver chemotherapy with them, rather than free-flowing chemotherapy in your bloodstream. And we’re learning more about the biology of small cell lung cancer and how certain patients may react better to certain drugs. So, all of these things should give patients a lot of hope when they are diagnosed with small cell lung cancer,” says Dr. Saxena.

Why Clinical Trials Matter

For years, people with SCLC had few treatment options. Now, research is expanding what may be possible, from new treatment approaches to a better understanding of distinct types of SCLC that could lead to more personalized care.

For patients, that progress means something especially important: hope.

Living Better, Not Just Longer

The research happening in clinical trials isn’t focused only on extending life. Researchers are also paying closer attention to how patients feel while they are living it.

Along with tracking whether a tumor shrinks or how long a treatment keeps cancer from growing, clinical trials increasingly look at how treatment affects everyday life, including fatigue, breathing problems, pain, and emotional well-being.

“The goal is to have meaningful time, not just more time,” says Dr. Saxena.

These patient-reported outcomes can also provide clues about whether a treatment is working before the next scan. A cough may improve. Breathing may become easier. Energy may return.

Your Voice Is Part of Your Treatment

Patients can play another important role in their care: Speak up.

Reporting side effects and changes in how you feel can help doctors adjust medications or dosages and better manage symptoms, helping patients maintain their quality of life and potentially stay on treatment longer.

In clinical trials, that feedback also helps researchers understand how a therapy affects a person’s daily life, not just what appears on a scan.

For Wendy Brooks, who is living with small cell lung cancer and is a member of the LCFA's Voices of Hope Speakers Bureau, the pace of change is encouraging.

“I'm more hopeful today than I have ever been,” says Brooks.

For people facing SCLC, the message is simple: Don’t wait to ask about clinical trials. Ask early. Ask before treatment begins. And keep asking as your treatment journey continues.

That one question: “Is there a clinical trial that might be right for me?” could open a door you didn’t know was there.

Learn MoreTo hear the full conversation between Wendy Brooks and Dr. Ashish Saxena on the Hope With Answers podcast and learn more about small cell lung cancer research, clinical trials, and treatment, visit LCFAmerica.org.

About LCFALung Cancer Foundation of America (LCFA) is dedicated to dramatically improving survival rates and quality of life for people diagnosed with lung cancer. Through funding innovative research, amplifying patient stories, and raising awareness, LCFA brings hope to the millions impacted by the world’s deadliest cancer. Learn more at LCFAmerica.org

Article Link